Inotek Commences Phase 1 Trial In Glaucoma With Selective Adenosine 1 A1 Agonist

Inotek Pharmaceuticals Corporation announced that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: